Much like MPD, MRI-FGT has been shown to be associated with breast cancer risk6, and sensitive to endogenous (e.g., menopause) and exogenous (e.g., tamoxifen, aromatase inhibitors) hormonal exposures7–9. This evidence concerns the gene CYP19A1 and breast cancer.